Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minocycline may cause hair loss by increasing DHT levels, but finasteride can help counteract this effect.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This study found that chronic administration of testosterone in mice induced an elevated EPO secretion response, possibly mediated through DHT, without affecting baseline EPO levels.

Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.

This study observed that finasteride, especially when combined with electrolysis, effectively reduced hair growth in women with hirsutism over six months.

This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.

This study analyzed self-reports from discussion forums to categorize and understand adverse effects experienced by individuals using finasteride, suggesting a need for further investigation into post-finasteride syndrome.

This study found that finasteride-induced androgen deficiency in an animal model resulted in tear deficiency and increased inflammatory cytokine expression in the lacrimal gland, potentially aiding in understanding dry eye pathogenesis.

This case study describes a 19-year-old female with hidradenitis suppurativa whose symptoms and metabolic abnormalities improved significantly over 3 years on a combined regimen, though some skin lesions persisted.

This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This research found that ethosomes significantly enhanced finasteride delivery into the dermis of human cadaver skin compared to liposomes in an in vitro study.

In this study, researchers found that finasteride exhibits a solid-solid phase relationship that is enantiotropic at normal pressure and becomes monotropic at higher pressure.

This study suggests that finasteride treatment may improve pulmonary immune response in mice following trauma and sepsis, indicating potential as a therapeutic option after major trauma.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

In this study, finasteride doubled the duration of the first off-cycle in intermittent androgen deprivation therapy for mice with LNCaP tumors but did not improve overall survival.

This study found that finasteride treatment in men with benign prostate hyperplasia significantly altered steroid hormone profiles and may contribute to depressive symptoms by affecting neuroactive steroid levels.

This study found no significant difference between alpha-blockers and finasteride in contributing to erectile dysfunction among men with other risk factors, with age and other underlying conditions being stronger influences.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.

This article discusses using high performance liquid chromatography to optimize mobile phase composition for separating synthesis products of Finasteride, without reporting new clinical results.

Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This study found that a short course of finasteride improved oxygen saturation but had no significant impact on mortality rate or length of hospital stay in older male COVID-19 pneumonia patients.

Finasteride reduces opioid use and withdrawal symptoms in animals.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

This study found differences in urinary androgen and estrogen concentrations between male pattern baldness patients treated with finasteride and healthy controls, suggesting potential biomarkers for post-finasteride syndrome.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study found that post-finasteride syndrome patients showed a tissue-specific methylation pattern of the SRD5A2 promoter in cerebrospinal fluid, potentially affecting neuroactive steroid levels and related behavioral symptoms.

This study found that long-term treatment with 1 mg/day finasteride over 10 years resulted in high efficacy and prevention of disease progression in Japanese men with androgenetic alopecia, with no serious adverse reactions reported.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.